单日狂揽4.65亿元，高人气创新药“新势力”——520880规模升值9.8亿元！标的指数官宣剔除CXO

Core Viewpoint - The Hong Kong Stock Exchange's innovative drug ETF (520880) experienced a volatile trading session, initially rising over 3% before closing down 1.6% on July 31, 2025, despite strong investor interest and significant capital inflows [1][2]. Group 1: ETF Performance - The Hong Kong Stock Exchange innovative drug ETF (520880) saw a significant increase in scale, reaching 986 million CNY, a 140% surge since its launch on July 7, 2025 [2][6]. - The ETF recorded a net inflow of 465 million CNY on a single day, with a total of 659 million CNY in net inflows over the past three days [2][6]. - The ETF's underlying index, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, has risen by 101.58% year-to-date as of July 31, 2025, outperforming the Hang Seng Index and the Hang Seng Technology Index by 78.08 and 79.53 percentage points, respectively [6][7]. Group 2: Index Composition and Adjustments - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index focuses on innovative drug research and development companies, with a high concentration of leading stocks [4][8]. - Recent adjustments to the index will exclude companies primarily engaged in CXO (Contract Research Organization) services, ensuring the index reflects a pure focus on innovative drug development [8][12]. - The decision to remove CXO companies is aimed at enhancing the index's performance by avoiding disturbances from service-oriented firms, thereby showcasing the maturity of China's innovative drug sector [12].